Guggenheim Capital LLC Ab Cellera Biologics Inc. Transaction History
Guggenheim Capital LLC
- $14 Billion
- Q3 2024
A detailed history of Guggenheim Capital LLC transactions in Ab Cellera Biologics Inc. stock. As of the latest transaction made, Guggenheim Capital LLC holds 10,362 shares of ABCL stock, worth $30,257. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,362
Previous 11,284
8.17%
Holding current value
$30,257
Previous $33,000
21.21%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding ABCL
# of Institutions
154Shares Held
109MCall Options Held
153KPut Options Held
194K-
Baker Bros. Advisors LP New York, NY27.5MShares$80.4 Million0.76% of portfolio
-
Baillie Gifford & CO12.9MShares$37.7 Million0.03% of portfolio
-
Voya Investment Management LLC Atlanta, GA10.6MShares$31 Million0.03% of portfolio
-
Prosight Management, LP Dallas, TX9.08MShares$26.5 Million6.31% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL4.59MShares$13.4 Million0.0% of portfolio
About AbCellera Biologics Inc.
- Ticker ABCL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 285,139,008
- Market Cap $833M
- Description
- AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...